All 2011 Releases
 |
The European Commission Grants Marketing Authorization for DIFICLIR™ (fidaxomicin) Tablets for Treatment of Clostridium difficile Infections
12.12.2011
|
12.8 KB |
|
| |
SAN DIEGO, Dec. 12, 2011 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) and Astellas Pharma Europe Ltd., a European subsidiary of Tokyo-based Astellas Pharma Inc. (Tokyo: 4503) announced today that the European Commission has granted Marketing Authorization (MA) for DIFICLIR™ (fidaxomicin) tablets for the treatment of adults wit...
|
|
Data Suggest Optimer's DIFICID® Provides Economic Value in the Treatment of Clostridium difficile-associated Diarrhea
12.06.2011
|
16.1 KB |
|
| |
SAN DIEGO, Dec. 6, 2011 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) announced today that data being presented at the American Society of Health-System Pharmacists 46th Midyear Clinical Meeting demonstrate that the economic value of DIFICID® (fidaxomicin) tablets to the U.S. health system meets or exceeds the price per day to t...
|
|
Optimer Pharmaceuticals to Present at Oppenheimer's 22nd Annual Healthcare Conference
12.01.2011
|
8.7 KB |
|
| |
SAN DIEGO, Dec. 1, 2011 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) today announced that the Company will present at the 22nd Annual Oppenheimer Healthcare Conference on Wednesday, December 14 at 2:45 PM Eastern Time.
(Logo: http://photos.prnewswire.com/prnh/20090413/LA97352LOGO)
A live audio webcast of the presentat...
|
|
Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
12.01.2011
|
8.5 KB |
|
| |
SAN DIEGO, Dec. 1, 2011 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) announced today that on November 30, 2011 the Compensation Committee of its Board of Directors approved the grant of inducement stock options to purchase an aggregate of 46,250 shares of common stock to 5 new employees.
(Logo: http://photos.prnewswire.com/p...
|
|
Optimer Pharmaceuticals to Webcast Investor and Analyst Reception on December 5th
11.28.2011
|
9.1 KB |
|
| |
SAN DIEGO, Nov. 28, 2011 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) will host investors and analysts in New York City on December 5, 2011 for a corporate overview and update with a focus on its commercial strategy and launch of DIFICID. A live webcast of the event will begin at 8:30 a.m. Eastern time and will be accessible on th...
|
|
Optimer Pharmaceuticals Reports Third Quarter 2011 Financial Results
11.03.2011
|
20.8 KB |
|
| |
SAN DIEGO, Nov. 3, 2011 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) today announced the Company's financial results for the quarter ended September 30, 2011.
(Logo: http://photos.prnewswire.com/prnh/20090413/LA97352LOGO)
Optimer reported total revenues for the third quarter of 2011 of $11.1 million, compared $669,000 for the...
|
|
Optimer Files New Drug Submission for DIFICID™ in Canada, Creates Canadian Subsidiary to Lead Commercial Effort
11.03.2011
|
13.8 KB |
|
| |
SAN DIEGO and TORONTO, Nov. 3, 2011 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) announced today that the Company filed a new drug submission (NDS) with the Therapeutic Products Directorate of Health Canada (Health Canada) for DIFICID™ (fidaxomicin) tablets for the treatment of Clostridium difficile infection (CDI), also known...
|
|
Optimer Pharmaceuticals to Present at 20th Annual Credit Suisse Healthcare Conference
11.01.2011
|
8.7 KB |
|
| |
SAN DIEGO, Nov. 1, 2011 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) today announced that the Company will present at the 20th Annual Credit Suisse Healthcare Conference on Thursday, November 10 at 10:00 AM Eastern Time (7:00 AM Pacific Time).
(Logo: http://photos.prnewswire.com/prnh/20090413/LA97352LOGO)
A live audio webcast...
|
|
Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
11.01.2011
|
8.8 KB |
|
| |
SAN DIEGO, Nov. 1, 2011 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) announced today that on October 31, 2011 the Compensation Committee of its Board of Directors approved the grant of inducement stock options to purchase an aggregate of 140,750 shares of common stock to 8 new employees.
(Logo: http://photos.prnewswire.com/prnh/...
|
|
Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2011 Financial Results
10.27.2011
|
9.1 KB |
|
| |
SAN DIEGO, Oct. 27, 2011 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today announced it will report third quarter 2011 financial results after the NASDAQ Global Market closes on November 3. The Company will host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) to discuss the financial results and highl...
|
|
DIFICID™ Demonstrated Early Superiority in the First 12 Days Compared to Vancomycin in New Analysis of Phase 3 Study Results
10.20.2011
|
15.7 KB |
|
| |
SAN DIEGO, Oct. 20, 2011 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) announced today that data being presented at the 49th Annual Meeting of the Infectious Diseases Society of America (IDSA) demonstrate that patients treated with DIFICID™ (fidaxomicin) tablets for Clostridium difficile-associated diarrhea (CDAD) experienced f...
|
|
Peggy Lillis Foundation honors Dr. Sherwood Gorbach for career combating C. diff infection
10.17.2011
|
12.9 KB |
|
| |
...
|
|
Optimer Pharmaceuticals' DIFICID Featured in Presentations at 49th Annual Meeting of IDSA
10.13.2011
|
13.8 KB |
|
| |
SAN DIEGO, Oct. 13, 2011 /PRNewswire/ -- Optimer Pharmaceuticals (NASDAQ: OPTR) today announced that new research findings for DIFICID™ (fidaxomicin) tablets will be featured in presentations at the 49th Annual Meeting of the Infectious Diseases Society of America (IDSA) occurring October 20-23 in Boston. The presentations include one late-b...
|
|
Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
10.03.2011
|
8.7 KB |
|
| |
SAN DIEGO, Oct. 3, 2011 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) announced today that on September 30, 2011, the Compensation Committee of its Board of Directors approved the grant of inducement stock options to purchase an aggregate of 133,000 shares of common stock to 7 new employees.
(Logo: http://photos.prnewswire.com/prn...
|
|
Optimer Pharmaceuticals to Present at BioCentury Newsmakers Conference
10.03.2011
|
8.6 KB |
|
| |
SAN DIEGO, Oct. 3, 2011 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) today announced that the Company will present at the 2011 BioCentury Newsmakers in the Biotech Industry conference on Friday, October 21 at 11:00 AM Eastern time.
(Logo: http://photos.prnewswire.com/prnh/20090413/LA97352LOGO )
A live audio webcast of the pre...
|
|
Optimer Pharmaceuticals and Astellas Receive Positive Opinion from CHMP for European Approval of DIFICID™
09.23.2011
|
12.3 KB |
|
| |
SAN DIEGO, Sept. 23, 2011 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for DIFICLIR™ (fidaxomicin) tablets for the treatment of adults suffering with a Clostridium difficile infec...
|
|
Optimer to Provide DIFICID™ Launch Update at Morgan Stanley Global Healthcare Conference
09.12.2011
|
18.0 KB |
|
| |
SAN DIEGO, Sept. 12, 2011 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) announced that the Company will provide an update on the DIFICID™ (fidaxomicin) tablets launch at the Morgan Stanley Global Healthcare Conference taking place in New York City. Pedro Lichtinger, Optimer's President and CEO, will comment on the DIFICID launc...
|
|
Optimer Pharmaceuticals' DIFICID Featured in 11 Presentations at 51st ICAAC
09.09.2011
|
15.6 KB |
|
| |
SAN DIEGO, Sept. 9, 2011 /PRNewswire/ -- Optimer Pharmaceuticals (NASDAQ: OPTR) today announced that 11 abstracts reporting new research findings for DIFICID™ (fidaxomicin) tablets will be presented at the 2011 Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) taking place September 17-20 in Chicago. DIFICID was approve...
|
|
Optimer Pharmaceuticals to Present at September 2011 Investor Conferences
09.01.2011
|
9.4 KB |
|
| |
SAN DIEGO, Sept. 1, 2011 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) today announced that the Company will present at the following investor conferences:
R.W. Baird Health Care Conference on Wednesday, September 7, 2011 at 12:45 p.m. Eastern Time at the New York Palace in New York.Morgan Stanley Global Healthcare Unplugged Confe...
|
|
Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
09.01.2011
|
8.9 KB |
|
| |
SAN DIEGO, Sept. 1, 2011 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) announced today that on August 31, 2011 the Compensation Committee of its Board of Directors approved the grant of inducement stock options to purchase an aggregate of 113,750 shares of common stock to 14 new employees.
(Logo: http://photos.prnewswire.com/prnh...
|
Delicious
Digg
Facebook
LinkedIn
Twitter